



# WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off. : B-9 & 10, Laxmi Towers, L.S.C., Block C, Saraswati Vihar, Delhi -110034.  
CIN No. L24232DL1996PLC227773

Date: 22.01.2022

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai-400001

**Scrip Code: 524661--Welcure Drugs & Pharmaceuticals Ltd.**

**Sub: Un-audited Financial Results for the Quarter and nine months ended 22.01.2022**

**Ref: Outcome of Board of Directors Meeting- 22<sup>nd</sup> January, 2022**

Respected Sir,

Pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today Saturday, 22<sup>nd</sup> January, 2022 at 11:30 am and concluded at 12:25 pm, *inter-alia*, approved the Un-Audited Financial Results of the Company for the Quarter and nine months ended 31<sup>st</sup> December, 2021.

We enclose copies of the following:

1. Un-audited Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2021;  
and
2. Limited Review Report of Un-Audited Financial Results for the said period.

We request you to take the same on record.

Thanking you

Yours faithfully

**For Welcure Drugs & Pharmaceuticals Limited**

  
(Mitashi Bisaria)

Director & Company Secretary  
DIN: 08660802



**Encl.: a/a**



*V.P. Gupta & Co.*

*Chartered Accountants*

**LIMITED REVIEW REPORT**  
**(For the Quarter & Nine months ended on December 31, 2021)**

To  
The Board of Directors,  
Welcure Drugs & Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Welcure Drugs & Pharmaceuticals Limited ("the Company") for the Quarter & Nine months ended December 31, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("the Regulations") as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular")
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors on 22<sup>nd</sup> January, 2022 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



288, Ghalib Apartments, Parwana Road, Pitampura, Delhi 110034, India

Ph. :- 91-11-27020321, 9313675636 Email:- tax@vpguptaandco.com



**V.P. Gupta & Co.**

*Chartered Accountants*

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, that has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

Place: Delhi  
Date: 22.01.2022

For V.P. Gupta & Co.  
Chartered Accountants  
FRN: 000699N



CA V.P Gupta  
Partner  
M No.: 080557  
UDIN: 22080557AAAAAI8038

**WELCURE DRUGS AND PHARMACEUTICALS LTD**

Regd. Office: B-9& 10, Laxmi Towers LSC, C-Block, Saraswati Vihar, Delhi-110034

CIN: L24232DL1996PLC227773

Email Id: investor.welcure@gmail.com

**Statement of Un-Audited Financial Results for the Quarter and Nine Months ended 31st December, 2021**

Sr. No.	Particulars	Quarter Ended			Nine months ended		(Figures in Lakhs)
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	Year ended 31-Mar-21
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	<b>Income</b>						
	a) Revenue from operations	-	-	-	-	-	-
	b) Other Operating Income	-	-	-	2.25	8.13	13.33
	<b>Total Income from operations (net)</b>	-	-	-	<b>2.25</b>	<b>8.13</b>	<b>13.33</b>
II	Other Income	-	-	-	-	0.06	0.02
III	<b>Total Income (I+II)</b>	-	-	-	<b>2.25</b>	<b>8.19</b>	<b>13.35</b>
IV	<b>Expenses</b>						
	(a) Cost of raw materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expenses	0.36	0.36	0.21	0.93	0.63	0.84
	(e) Finance Cost	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-	-
	(g) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	0.22	0.99	0.18	5.65	6.03	7.00
	<b>Total Expenses</b>	<b>0.58</b>	<b>1.35</b>	<b>0.39</b>	<b>6.58</b>	<b>6.66</b>	<b>7.84</b>
V	<b>Profit/ (Loss) Before Exceptional and Extraordinary Items and Tax (III-IV)</b>	<b>(0.58)</b>	<b>(1.35)</b>	<b>(0.39)</b>	<b>(4.33)</b>	<b>1.53</b>	<b>5.51</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit/ (Loss) before extraordinary items and Tax (V-VI)</b>	<b>(0.58)</b>	<b>(1.35)</b>	<b>(0.39)</b>	<b>(4.33)</b>	<b>1.53</b>	<b>5.51</b>
VIII	Extraordinary items	-	-	-	-	-	-
IX	<b>Profit before tax (VII- VIII)</b>	<b>(0.58)</b>	<b>(1.35)</b>	<b>(0.39)</b>	<b>(4.33)</b>	<b>1.53</b>	<b>5.51</b>
X	<b>Tax Expenses</b>						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
XI	<b>Profit (Loss) for the period from continuing operations (IX-X)</b>	<b>(0.58)</b>	<b>(1.35)</b>	<b>(0.39)</b>	<b>(4.33)</b>	<b>1.53</b>	<b>5.51</b>
XII	<b>Net Profit/ (Loss) from discontinuing operation (before Tax)</b>	-	-	-	-	-	-
XIII	Tax Expense of discontinuing operations	-	-	-	-	-	-
XIV	<b>Net Profit/ (Loss) from discontinuing operation after Tax (XII-XIII)</b>	-	-	-	-	-	-
XV	<b>Net Profit/ (Loss) for the Period (XI+XIV)</b>	<b>(0.58)</b>	<b>(1.35)</b>	<b>(0.39)</b>	<b>(4.33)</b>	<b>1.53</b>	<b>5.51</b>
XVI	Share of profit / (loss) of associates	-	-	-	-	-	-
XVII	Share of profit / (loss) of Minority	-	-	-	-	-	-
XVIII	<b>Net Profit/ (Loss) after taxes, minority interest and share of profit/(loss) of associates</b>	<b>(0.58)</b>	<b>(1.35)</b>	<b>(0.39)</b>	<b>(4.33)</b>	<b>1.53</b>	<b>5.51</b>
XIX	Other Comprehensive Income	-	-	-	-	-	-
XX	<b>Total Comprehensive Income for the period (XVIII+XIX)</b>	<b>(0.58)</b>	<b>(1.35)</b>	<b>(0.39)</b>	<b>(4.33)</b>	<b>1.53</b>	<b>5.51</b>
XXI	Paid-up share capital (Face value of Rs.10/- per share)	1,211.86	1,211.86	1,211.86	1,211.86	1,211.86	1,211.86
XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	(1,204.92)
XXIII	Earning Per Share (of Rs. 10/- each) (not annualised)						
	A) Basic	(0.00)	(0.01)	-	(0.04)	0.01	0.05
	B) Diluted						

**Notes:**

- The Statement of Un-audited Financial results for the Quarter and Nine months ended December 31, 2021 have been reviewed by the audit committee and approved by the Board of directors at their respective meetings held on 22nd January, 2022. There are no qualifications in Limited Review Report issued by the auditor.
- The financial results for the quarter and Nine months ended December 31, 2021 have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ( Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- There were no investor complaints pending during the Quarter ended December 31, 2021
- As the Company is mainly operating in one reportable business segment, hence the disclosure requirements of Indian Accounting Standard (Ind AS-108) "Operating Segment" is not applicable.
- The Previous Quarter ended figures have been re-grouped/ re-arranged, whenever necessary.
- There is no need to provide any reconciliation as required by the circular dated July 05, 2016, since there is no change in the figures due to transit from the previous Indian GAAP to Ind-AS.

Place: Delhi  
Date: 22.01.2022



For WELCURE DRUGS & PHARMACEUTICALS LIMITED

SUDHIR CHANDRA  
MANAGING DIRECTOR  
DIN: 00323545